SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published article

18 Oct 2013 07:00

RNS Number : 8024Q
Tristel PLC
18 October 2013
 



Tristel plc

("Tristel" or "the Company")

 

Peer-reviewed published article supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of an article in a peer-reviewed journal that describes the benefits of Tristel products.

 

The study is titled "A randomised single-blind comparison of the effectiveness of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Cidex OPA (ortho-phthaldehyde) for use with flexible cystoscopes". It has been published in The British Journal of Urology International (on line 10.1111 BJU 12208) and will be published within the Urological Society of Australia and New Zealand (special issue volume 112).

 

The article compares the effectiveness, safety and cost of Tristel's chlorine dioxide Fuse chemistry with Cidex OPA (Johnson & Johnson, USA), in an automated endoscope reprocessor (Medivators Inc, USA) for high level disinfection of flexible cystoscopes.

 

Tristel Fuse, which was used within the Company's Stella decontamination system, was found to be as effective, more economic and easier for the nursing staff to use than the American products with which it was compared.

 

Tristel CEO, Paul Swinney, commented: "This study was initiated in 2009 by the Department of Urology, Tauranga Hospital, New Zealand, and the initial results were reported at the Societe Internationale d'Urologie congress, Shanghai, 2011.

 

"This is the first published study that compares our Tristel Fuse and Stella system with one of the world's leading combinations of disinfectant and endoscope washing machine. It demonstrates that our chlorine dioxide technology is just as safe and effective as the world's most widely used medical instrument disinfectant, whilst producing cost savings for hospitals.

 

"This study joins the growing body of published scientific evidence demonstrating that Tristel products are superior to the incumbent technologies still being used around the world."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRANKODPPBDDDKD
Date   Source Headline
13th Oct 20168:33 amRNSIssue of Equity
12th Oct 20168:12 amRNSStudy shows Tristel Wipes System benefits
11th Oct 20167:00 amRNSStudy shows Tristel Wipes System benefits
20th Sep 20167:00 amRNSNotice of Results
19th Sep 20169:24 amRNSIssue of Equity
12th Sep 20167:00 amRNSRegulatory approval in Australia for surface range
19th Aug 20164:30 pmRNSDirector/PDMR Shareholding
19th Aug 20161:30 pmRNSIssue of Equity
21st Jul 20163:26 pmRNSDirector Dealing
21st Jul 20167:00 amRNSTrading update, Special dividend & Acquisition
25th May 20167:00 amRNSShareholder Open Day & Notice of Trading Update
29th Apr 201611:06 amRNSDirector Dealing
26th Apr 201610:06 amRNSDirector Dealing
15th Mar 20167:00 amRNSDirector Dealing
11th Mar 20167:00 amRNSDirector Dealing
10th Mar 20167:00 amRNSDirector Dealing
2nd Mar 20165:13 pmRNSDirector Dealing
2nd Mar 20169:46 amRNSDirector Dealing
29th Feb 20167:00 amRNSDirector Dealing
26th Feb 20169:43 amRNSDirectors Dealings
24th Feb 20167:00 amRNSHalf Yearly Report
25th Jan 20167:00 amRNSNotice of Results
13th Jan 20164:53 pmRNSIssue of Equity
5th Jan 20167:00 amRNSTransition of German branch to subsidiary status
15th Dec 20151:43 pmRNSDirectors Dealings
15th Dec 201512:18 pmRNSResult of AGM
15th Dec 20157:00 amRNSAGM Statement
2nd Dec 201511:37 amRNSIssue of Equity
1st Dec 201511:06 amRNSPosting of Annual Report & Notice of AGM
1st Dec 201511:05 amRNSFrench study shows superiority of Tristel Wipes
2nd Nov 20153:42 pmRNSIssue of Equity
22nd Oct 20154:02 pmRNSIssue of Equity
15th Oct 20159:50 amRNSIssue of Equity/Director Dealing
12th Oct 20157:00 amRNSFinal Results
5th Oct 20157:00 amRNSInvestor results briefing - Change of venue
1st Oct 20157:00 amRNSAppointment of Non-Executive Director
25th Sep 20151:52 pmRNSIssue of Equity
18th Sep 20157:00 amRNSNotice of Results
18th Aug 201510:14 amRNSIssue of Equity
17th Aug 20151:07 pmRNSDirector Share Transfer
6th Aug 201511:01 amRNSIssue of Equity
4th Aug 201511:57 amRNSDirectors dealing/grant of options
20th Jul 20154:25 pmRNSIssue of Equity
30th Jun 20154:59 pmRNSIssue of Equity
24th Jun 20154:08 pmRNSIssue of Equity
23rd Jun 20153:15 pmRNSIssue of Equity
18th Jun 20159:00 amRNSDirector Dealing/Issue of Equity
18th Jun 20157:00 amRNSSpecial Dividend and notice of results
9th Jun 20151:44 pmRNSTristel welcomes Cardiff University wipes study
3rd Jun 201512:20 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.